Opus Genetics, Inc. (IRD) 10-Year Financial Performance & Capital Metrics

IRD • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutOpus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.Show more

Revenue $11M -42.3%
EBITDA -$62M -487.9%
Net Income -$58M -476.1%
EPS (Diluted) -2.15 -367.4%
Gross Margin 100%
EBITDA Margin -564.63% -918.8%
Operating Margin -564.72% -918.4%
Net Margin -523.4% -898.4%
ROE -203.19% -878.1%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 23.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y165.25%

TTM74.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-150.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM-56.36%

ROCE

10Y Avg-166.52%

5Y Avg-166.52%

3Y Avg-44.41%

Latest-164.49%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	589K	39.85M	19.05M	10.99M
Revenue Growth %	-	-	-	66.66%	-0.52%	-0.42%
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	589K	39.85M	19.05M	10.99M
Gross Margin %	-	-	1%	1%	1%	1%
Gross Profit Growth %	-	-	-	66.66%	-0.52%	-0.42%
Operating Expenses+	4.19M	19.97M	23.29M	21.62M	29.61M	73.07M
OpEx % of Revenue	-	-	39.55%	0.54%	1.55%	6.65%
Selling, General & Admin	1.82M	2.82M	8.12M	7.27M	11.96M	18.21M
SG&A % of Revenue	-	-	13.79%	0.18%	0.63%	1.66%
Research & Development	2.37M	6.65M	15.17M	14.36M	17.65M	26.85M
R&D % of Revenue	-	-	25.76%	0.36%	0.93%	2.44%
Other Operating Expenses	0	10.5M	0	0	0	28M
Operating Income+	-4.19M	-19.97M	-22.7M	18.23M	-10.56M	-62.07M
Operating Margin %	-	-	-38.55%	0.46%	-0.55%	-5.65%
Operating Income Growth %	-	-3.76%	-0.14%	1.8%	-1.58%	-4.88%
EBITDA+	-4.19M	-19.96M	-22.7M	18.23M	-10.56M	-62.06M
EBITDA Margin %	-	-	-38.54%	0.46%	-0.55%	-5.65%
EBITDA Growth %	-	-3.76%	-0.14%	1.8%	-1.58%	-4.88%
D&A (Non-Cash Add-back)	3K	8K	4K	4K	6K	10K
EBIT	-4.76M	-17.77M	-56.69M	18.21M	-9.97M	-57.53M
Net Interest Income+	-1.41M	-6.85M	-2K	-9K	-1.33M	0
Interest Income	0	0	0	0	0	0
Interest Expense	1.41M	6.85M	2K	9K	1.33M	0
Other Income/Expense	-1.98M	-4.65M	-33.99M	-23K	589K	4.54M
Pretax Income+	-6.17M	-24.62M	-56.69M	18.2M	-9.97M	-57.53M
Pretax Margin %	-	-	-96.25%	0.46%	-0.52%	-5.23%
Income Tax+	0	0	0	315K	12K	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%
Net Income+	-6.17M	-24.62M	-56.69M	17.89M	-9.99M	-57.53M
Net Margin %	-	-	-96.25%	0.45%	-0.52%	-5.23%
Net Income Growth %	-	-2.99%	-1.3%	1.32%	-1.56%	-4.76%
Net Income (Continuing)	-6.17M	-24.62M	-56.69M	17.89M	-9.99M	-57.53M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.87	-5.28	-3.82	0.87	-0.46	-2.15
EPS Growth %	-	-5.07%	0.28%	1.23%	-1.53%	-3.67%
EPS (Basic)	-0.87	-5.28	-3.82	0.90	-0.46	-2.15
Diluted Shares Outstanding	7.09M	4.66M	14.85M	20.6M	21.59M	26.72M
Basic Shares Outstanding	7.09M	4.66M	14.85M	19.93M	21.59M	26.72M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.76M	17.67M	26.07M	48.99M	53.95M	36.61M
Cash & Short-Term Investments	1.54M	16.4M	24.75M	42.68M	50.52M	30.32M
Cash Only	1.54M	16.4M	24.53M	42.63M	50.5M	30.32M
Short-Term Investments	0	0	219K	49K	15K	2K
Accounts Receivable	125K	0	0	4.85M	2.33M	5.77M
Days Sales Outstanding	-	-	-	44.42	44.7	191.66
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	81K	26K	71K	80K	102K	515K
Total Non-Current Assets+	22K	14K	10K	6K	0	252K
Property, Plant & Equipment	22K	14K	10K	6K	0	252K
Fixed Asset Turnover	-	-	58.90x	6641.67x	-	43.62x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	1.78M	17.68M	26.08M	48.99M	53.95M	36.86M
Asset Turnover	-	-	0.02x	0.81x	0.35x	0.30x
Asset Growth %	-	8.91%	0.47%	0.88%	0.1%	-0.32%
Total Current Liabilities+	9.34M	3.19M	3.85M	2.75M	4.04M	11.29M
Accounts Payable	342K	1.21M	1.58M	1.07M	2.15M	3.15M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	5.67M	0	538K	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	2.71M	0	0	0	74K	2K
Current Ratio	0.19x	5.55x	6.76x	17.79x	13.35x	3.24x
Quick Ratio	0.19x	5.55x	6.76x	17.79x	13.35x	3.24x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	27.96M	0	0	0	18.84M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	27.96M	0	0	0	18.84M
Total Liabilities	9.34M	31.15M	3.85M	2.75M	4.04M	30.14M
Total Debt+	5.67M	0	538K	0	0	0
Net Debt	4.13M	-16.4M	-24M	-42.63M	-50.5M	-30.32M
Debt / Equity	-	-	0.02x	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-2.34x	-	-
Interest Coverage	-2.98x	-2.92x	-11352.50x	2025.11x	-7.95x	-
Total Equity+	-7.56M	-13.47M	22.22M	46.24M	49.91M	6.72M
Equity Growth %	-	-0.78%	2.65%	1.08%	0.08%	-0.87%
Book Value per Share	-1.07	-2.89	1.50	2.24	2.31	0.25
Total Shareholders' Equity	-7.56M	-13.47M	22.22M	46.24M	49.91M	6.72M
Common Stock	0	1K	2K	2K	2K	3K
Retained Earnings	-8.05M	-32.67M	-89.37M	-71.48M	-81.47M	-139M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.59M	-6.8M	-19.37M	14.31M	-1.11M	-25.58M
Operating CF Margin %	-	-	-32.89%	0.36%	-0.06%	-2.33%
Operating CF Growth %	-	-0.89%	-1.85%	1.74%	-1.08%	-22%
Net Income	-6.17M	-24.62M	-56.69M	17.89M	-9.99M	-57.53M
Depreciation & Amortization	3K	8K	4K	4K	6K	10K
Stock-Based Compensation	308K	1.51M	1.91M	1.81M	3.51M	3.36M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	1.91M	15.16M	35.22M	170K	1.28M	25.49M
Working Capital Changes	357K	1.15M	181K	-5.55M	4.08M	3.09M
Change in Receivables	0	0	0	-4.85M	2.52M	-3.44M
Change in Inventory	0	0	0	0	0	0
Change in Payables	-168K	792K	381K	-515K	1.08M	220K
Cash from Investing+	-25K	539K	-100K	0	0	1.21M
Capital Expenditures	-25K	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	539K	-100K	0	0	1.21M
Cash from Financing+	4.7M	21.12M	27.61M	3.79M	8.98M	4.19M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-2K	-2.23M	-1.42M	-104K	-248K	-232K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-3.62M	-6.8M	-19.37M	14.31M	-1.11M	-25.58M
FCF Margin %	-	-	-32.89%	0.36%	-0.06%	-2.33%
FCF Growth %	-	-0.88%	-1.85%	1.74%	-1.08%	-22%
FCF per Share	-0.51	-1.46	-1.30	0.69	-0.05	-0.96
FCF Conversion (FCF/Net Income)	0.58x	0.28x	0.34x	0.80x	0.11x	0.44x
Interest Paid	0	0	2K	9K	0	0
Taxes Paid	0	0	0	0	344K	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-1295.1%	52.26%	-20.77%	-203.19%
Return on Invested Capital (ROIC)	-	-	-	1493.12%	-526.4%	-
Gross Margin	-	-	100%	100%	100%	100%
Net Margin	-	-	-9625.3%	44.89%	-52.42%	-523.4%
Debt / Equity	-	-	0.02x	-	-	-
Interest Coverage	-2.98x	-2.92x	-11352.50x	2025.11x	-7.95x	-
FCF Conversion	0.58x	0.28x	0.34x	0.80x	0.11x	0.44x
Revenue Growth	-	-	-	6665.7%	-52.2%	-42.3%

Frequently Asked Questions

Growth & Financials

Opus Genetics, Inc. (IRD) reported $14.6M in revenue for fiscal year 2024.

Opus Genetics, Inc. (IRD) saw revenue decline by 42.3% over the past year.

Opus Genetics, Inc. (IRD) reported a net loss of $68.2M for fiscal year 2024.

Dividend & Returns

Opus Genetics, Inc. (IRD) has a return on equity (ROE) of -203.2%. Negative ROE indicates the company is unprofitable.

Opus Genetics, Inc. (IRD) had negative free cash flow of $32.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener